$250.98
2.49% yesterday
Nasdaq, Nov 25, 10:02 pm CET
ISIN
US02043Q1076
Symbol
ALNY
Sector
Industry

Alnylam Pharmaceuticals, Inc Stock price

$250.98
-33.88 11.89% 1M
+103.22 69.86% 6M
+59.57 31.12% YTD
+91.78 57.65% 1Y
+62.18 32.93% 3Y
+138.56 123.25% 5Y
+153.77 158.18% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+6.09 2.49%
ISIN
US02043Q1076
Symbol
ALNY
Sector
Industry

Key metrics

Market capitalization $32.37b
Enterprise Value $32.32b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 2,012.30
EV/Sales (TTM) EV/Sales 15.43
P/S ratio (TTM) P/S ratio 15.45
P/B ratio (TTM) P/B ratio 999.44
Revenue growth (TTM) Revenue growth 21.54%
Revenue (TTM) Revenue $2.09b
EBIT (operating result TTM) EBIT $-188.13m
Free Cash Flow (TTM) Free Cash Flow $16.06m
Cash position $2.78b
EPS (TTM) EPS $-2.62
P/E forward negative
P/S forward 14.51
EV/Sales forward 14.48
Short interest 3.30%
Show more

Is Alnylam Pharmaceuticals, Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Alnylam Pharmaceuticals, Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

23x Buy
70%
8x Hold
24%
2x Sell
6%

Analyst Opinions

33 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

Buy
70%
Hold
24%
Sell
6%

Financial data from Alnylam Pharmaceuticals, Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,095 2,095
22% 22%
100%
- Direct Costs 306 306
11% 11%
15%
1,788 1,788
24% 24%
85%
- Selling and Administrative Expenses 822 822
9% 9%
39%
- Research and Development Expense 1,098 1,098
10% 10%
52%
-132 -132
56% 56%
-6%
- Depreciation and Amortization 56 56
2% 2%
3%
EBIT (Operating Income) EBIT -188 -188
47% 47%
-9%
Net Profit -332 -332
35% 35%
-16%

In millions USD.

Don't miss a Thing! We will send you all news about Alnylam Pharmaceuticals, Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alnylam Pharmaceuticals, Inc Stock News

Neutral
Business Wire
one day ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental New Drug Application (sNDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM...
Neutral
Business Wire
9 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran (formerly ALN-TTRsc04), a next-generation RNAi therapeutic in development for the treatment of transthyretin (ATTR) amyloidosis. The data were presented in an oral session at the American Hear...
Neutral
Business Wire
22 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 8:45 am PT (11:45 ET) at the Terranea Resort in Ranchos Palos Verdes, CA Jefferies London Healthcare Conference on Wed...
More Alnylam Pharmaceuticals, Inc News

Company Profile

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Head office United States
CEO Yvonne Greenstreet
Employees 2,100
Founded 2002
Website www.alnylam.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today